Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: The GLOW6 study

International Journal of COPD

Volumn 9, Issue , 2014, Pages 215-228

  Vincken, Walter ^a   Aumann, Joseph ^b   Chen, Hungta ^c   Henley, Michelle ^c   McBryan, Danny ^c   Goyal, Pankaj ^c  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b Longartsenpraktijk Prins Bisschopssingel   (Belgium)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Breezhaler ; Bronchodilation; COPD; Glycopyrronium; Indacaterol; Inhalation therapy

Indexed keywords

GLYCOPYRRONIUM BROMIDE; INDACATEROL; PLACEBO;

ACUTE KIDNEY FAILURE; ADULT; ANGINA PECTORIS; ARTICLE; BACKACHE; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH STATUS; HEART DISEASE; HEMOPTYSIS; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; INFLUENZA; INGUINAL HERNIA; INTOXICATION; KIDNEY DISEASE; LIMB PAIN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MIDDLE AGED; MONOTHERAPY; MUSCULOSKELETAL DISEASE; OROPHARYNX PAIN; OSTEITIS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; RIB FRACTURE; SCORING SYSTEM; SPIROMETRY; SYNDROME DELINEATION; THORAX DISEASE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION;

BREEZHALER®; BRONCHODILATION; COPD; GLYCOPYRRONIUM; INDACATEROL; INHALATION THERAPY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; AREA UNDER CURVE; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; FORCED EXPIRATORY VOLUME; GLYCOPYRROLATE; HUMANS; INDANS; INSPIRATORY CAPACITY; LUNG; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84894777849     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S51592     Document Type: Article

References (42)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: http://www.goldcopd.org/. Accessed on January 8, 2014.
2. Cazzola M, Matera MG. Long-acting bronchodilators are the first-choice option for the treatment of stable COPD. Chest. 2004;125(1):9-11.
3. European Medicines Agency (EMA). Seebri Breezhaler (glycopyrronium bromide: summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002430/WC500133769.pdf. Accessed June 25, 2013.
4. Novartis Global. Novartis receives European Commission approval for once-daily Seebri® Breezhaler® as maintenance COPD treatment in the EU [press release]. Basel, Switzerland: Novartis; 2012 [October 1]. Available from: http://www.novartis.com/newsroom/media-releases/en/2012/1645116.shtml. Accessed 22 November, 2012.
5. European Medicines Agency (EMA). Bretaris Genuair (aclidinium bromide): summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002706/WC500132732.pdf. Accessed June 25, 2013.
6. European Medicines Agency (EMA). Eklira Genuair (aclidinium bromide): summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002211/WC500132661.pdf. Accessed June 25, 2013.
7. US Food and Drug Administration (FDA). Tudorza Pressair (aclidinium bromide): US prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202450s000lbl.pdf. Accessed June 25, 2013.
8. Beeh KM, Singh D, Di SL, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503-513.
9. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B. Long-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140(1):68-75.
10. D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011;12:156.
11. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily longacting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473-479.
12. Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155-162.
13. Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106-1114.
14. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2):273-279.
15. Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med. 2011;105(5):719-726.
16. Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38(4):797-803.
17. Vogelmeier C, Ramos-Barbon D, Jack D, et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res. 2010;11:135.
18. van Noord JA, Aumann JL, Janssens E, et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med. 2010;104(7):995-1004.
19. Vincken W. An update of bronchodilator treatment of chronic obstructive pulmonary disease (COPD) [abstract]. Ann Respir Med. 2010;1:1-16.
20. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol monoand combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102(11):1511-1520.
21. Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax. 2012;67(9):781-788.
22. Maltais F, Beck E, Webster D, et al. Four weeks once daily treatment with tiotropium + olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract]. Eur Respir J. 2010;36:5557.
23. Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med. 2008;102(4):479-487.
24. Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009;6(1):17-25.
25. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006;129(3):509-517.
26. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26(2):214-222.
27. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013 Dec;42(6):1484-1494.
28. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. Available from: http://www.goldcopd.org/. Accessed November 23, 2013.
29. Clinicaltrials.gov identifier NCT01604278. http://clinicaltrials.gov/show/NCT01604278. Accessed on 16th January 2014.
30. Mozzicato P. MedDRA. An Overview of the Medical Dictionary for Regulatory Activities. Pharm Med. 2009;23:65-75.
31. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003;21(2):267-272.
32. Jones PW. St George's Respiratory Questionnaire: MCID. COPD. 2005;2(1):75-79.
33. [No authors listed]. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest. 1994;105(5):1411-1419.
34. [No authors listed]. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group. Chest. 1997;112(6):1514-1521.
35. Mahler DA, Decramer M, D'Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study. Eur Respir J. October 31, 2013. [Epub ahead of print].
36. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217-224.
37. Yawn BP, Kaplan A. Co-morbidities in people with COPD: a result of multiple diseases, or multiple manifestations of smoking and reactive inflammation? Prim Care Respir J. 2008;17(4):199-205.
38. Calverley PM, Rennard SI. What have we learned from large drug treatment trials in COPD? Lancet. 2007;370(9589):774-785.
39. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171-1178.
40. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002;19(2):209-216.
41. Vogelmeier C, Bateman E, Pallante J, et al. Efficacy and safety of oncedaily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51-60.
42. Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2013;22(1): 92-100